Related Experiment Video
Updated: Aug 10, 2026

09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Utility of flow cytometry in subtyping composite and sequential lymphoma
J D Siebert1, D A Mulvaney, A M Vukov
1Department of Pathology, OSF Saint Francis Medical Center, Peoria, Illinois 61637, USA.
Journal of Clinical Laboratory Analysis
|September 24, 1999
Summary
Flow cytometry aids in diagnosing composite lymphoma (CL) and sequential lymphoma (SL) by identifying distinct B-cell populations. This technique is valuable for characterizing these complex lymphoma cases.
Area of Science:
- Hematology
- Oncology
- Immunophenotyping
Background:
- Composite lymphoma (CL) and sequential lymphoma (SL) involve multiple distinct lymphoma variants.
- Previous studies on flow cytometry's utility in CL/SL are limited.
Purpose of the Study:
- To evaluate the utility of flow cytometry immunophenotyping in characterizing CL and SL.
- To define the role of flow cytometry in differentiating lymphoma subtypes within CL and SL cases.
Main Methods:
- Retrospective review of four CL/SL cases from two institutions.
- Morphological evaluation of H&E-stained tissue sections and subtyping using REAL criteria.
- Immunophenotyping using two-color flow cytometry and paraffin-section immunostains.
Main Results:
- Flow cytometry identified distinct monoclonal B-cell populations in Case 1 (follicle center and marginal zone CL).
- Case 2 demonstrated consistent CD5-/CD10-/CD19+/kappa+ cells in both lymphoplasmacytoid and Hodgkin's disease components.
- Distinct immunophenotypes were observed for the different lymphoma components in Cases 3 and 4, including T-cell and B-cell lymphomas.
Conclusions:
- Flow cytometry is a potentially useful adjunct for characterizing composite and sequential lymphomas.
- Immunophenotyping can help differentiate the distinct lymphoma components in CL and SL.
- Further studies are warranted to establish flow cytometry as a standard tool for CL/SL evaluation.

